ライフサイエンスコーパス: releasing factor

1 induced by the stress hormone, corticotropin releasing factor.

2 alize with the stress hormone, corticotropin releasing factor.

3 were depolarised by exogenous corticotrophin releasing factor.

4 mone 44 (DH44), an ortholog of corticotropin-releasing factor.

5 y active clinical candidate of corticotropin-releasing factor 1 (CRF 1) antagonist 1 showed a signifi

6 ally active antagonists of the corticotropin-releasing factor 1 (CRF 1) receptor.

7 de), D2R agonist (quinpirole), corticotropin-releasing factor 1 (CRF1) antagonist (antalarmin), and a

8 ne domains of the glucagon and corticotropin releasing factor 1 (CRF1) receptors to develop improved

9 Ablation of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1), a neuronal activator of R

10 examined the role of Ras Guanine Nucleotide Releasing Factor 1 (RasGRF1) and 2 (RasGRF2), upstream r

11 n of Ras protein-specific guanine nucleotide releasing factor 1 (RasGrf1), a Ras activator (5-fold, P

12 with Ras protein-specific guanine nucleotide-releasing factor 1 (RASGRF1), leading to impaired activa

13 armacologic inhibition (with a corticotropin-releasing factor 1 receptor antagonist) of pain-related

14 earlier lead pyrazinone-based corticotropin-releasing factor-1 (CRF(1)) receptor antagonist, reveale

15 al-like state characterized by corticotropin-releasing factor-1 (CRF(1)) receptor antagonist-reversib

16 Evidence suggests that corticotropin-releasing factor-1 (CRF(1)) receptor antagonists may off

17 ed as potent and orally active corticotropin-releasing factor-1 (CRF(1)) receptor antagonists.

18 s to palatable food results in corticotropin-releasing factor-1 (CRF1) receptor antagonist-reversible

19 26907 in the ras-specific guanine-nucleotide releasing factor 2 (RASGRF2) gene, encoding a protein th

20 e processes; Ras-specific guanine nucleotide releasing factor 2 (RasGRF2).

21 ene (Ras protein-specific guanine nucleotide-releasing factor 2) with all clinical events except stro

22 After considering the releasing factor (66.6%) from the swab, the final accura

23 Corticotropin-releasing factor, a stress-related neuropeptide implicat

24 id peptide function, increased corticotropin-releasing factor activity).

25 ess neurotransmitters, such as corticotropin-releasing factor and dynorphin, in the neurocircuitry of

26 ing by increased expression of corticotropin-releasing factor and its feedback regulation of TLR4 exp

27 and Hcrt systems in which the corticotropin-releasing factor and N/OFQ systems coordinately modulate

28 stress and resilience, such as corticotropin-releasing factor and nociceptin, has been postulated to

29 sensitizes the LC-NE system to corticotropin releasing factor and stress.

30 ism in the brain to counteract corticotropin-releasing factor and/or stress.

31 cretin/orexin, norepinephrine, corticotropin-releasing factor, and cytokines.

32 ral stress response induced by corticotropin releasing factor, and promoting stress resilience.

33 PA axis-based interventions of corticotropin-releasing factor antagonists and the glucocorticoid rece

34 (especially neuropeptide Y and corticotropin-releasing factor) are modulated by alcohol drinking duri

35 Corticotropin releasing factor binding protein (CRF-BP) was originally

36 Corticotropin releasing factor-binding protein (CRF-BP) binds CRF and

37 Corticotropin-releasing factor binds with high affinity to CRF recepto

38 ed Crk SH3 domain-binding guanine-nucleotide releasing factor (C3G) binding to CrkII, whereas inhibit

39 Infusion of hypothalamic-releasing factors can reactivate the thyroid axis in pat

40 othalamus and primarily in non-corticotropin releasing factor-containing neurons of the bed nucleus o

41 os activation were observed in corticotropin releasing factor-containing neurons of the paraventricul

42 at baseline and in response to corticotropin-releasing factor (CRF) (0.5 microg kg(1)) plus arginine

43 BDNF signaling is mediated by corticotrophin-releasing factor (CRF) acting in the NAc.

44 s, including a coordination of corticotropin-releasing factor (CRF) actions at both of its receptors,

45 We report that corticotropin-releasing factor (CRF) acts in the ventral tegmental are

46 also posit a central role for corticotrophin-releasing factor (CRF) and an interaction between CRF an

47 tine SA on the coexpression of corticotropin-releasing factor (CRF) and arginine vasopressin (AVP) mR

48 gh it has long been known that corticotropin-releasing factor (CRF) and CRF receptors are prominent i

49 esent review is on the role of corticotropin-releasing factor (CRF) and CRF-related peptides in the d

50 ng-term alterations in central corticotropin-releasing factor (CRF) and glucocorticoid receptor (GR)

51 ion between the stress hormone corticotropin releasing factor (CRF) and glutamate release onto dopami

52 d to partially colocalize with corticotropin-releasing factor (CRF) and growth hormone-releasing horm

53 xtrahypothalamic expression of corticotropin-releasing factor (CRF) and its G-protein-coupled CRF1 an

54 The stress neuropeptide corticotropin releasing factor (CRF) and its receptors (CRF-R1, CRF-R2

55 Corticotropin-releasing factor (CRF) and nociceptin/orphanin FQ (nocic

56 europharmacological actions of corticotropin-releasing factor (CRF) and norepinephrine in extrahypoth

57 Release of the neuropeptides corticotropin-releasing factor (CRF) and orexin-A in the ventral tegme

58 Corticotropin-releasing factor (CRF) and related peptides play a role

59 Corticotropin-releasing factor (CRF) and the three related peptides ur

60 The corticotropin releasing factor (CRF) antagonist, alpha-helical CRF(9-4

61 e report the identification of corticotropin-releasing factor (CRF) as a critical component of the ca

62 Exogenous corticotropin-releasing factor (CRF) but not corticosterone mimicked t

63 ne arm of the stress response, corticotropin-releasing factor (CRF) can act in the brain to modulate

64 ase of neuromodulators such as corticotropin-releasing factor (CRF) can drive drug-dependent behavior

65 To investigate corticotropin-releasing factor (CRF) contributions to fear memory in L

66 Corticotropin releasing factor (CRF) coordinates the brains responses

67 e stress-related neuropeptide, corticotropin-releasing factor (CRF) directs this by a bimodal regulat

68 elease the stress neuropeptide corticotropin-releasing factor (CRF) drive anxiety-like behaviors in r

69 the central extrahypothalamic corticotropin-releasing factor (CRF) expression is associated with str

70 The corticotropin releasing factor (CRF) family of ligands and their recep

71 enced by the highly conserved corticotrophin-releasing factor (CRF) family of peptides and receptors

72 The corticotropin-releasing factor (CRF) family of peptides includes CRF a

73 tin 2 (Ucn2), a peptide of the corticotropin-releasing factor (CRF) family, binds with high affinity

74 n of the stress neuromediator, corticotropin-releasing factor (CRF) has been implicated in these diso

75 levant PI cells identified the corticotropin-releasing factor (CRF) homolog, DH44, as a circadian out

76 e self-administration, reduced corticotropin-releasing factor (CRF) immunodensity in the paraventricu

77 ence of somatostatin (SS) and corticotrophin-releasing factor (CRF) in forebrain neurons that project

78 lation of cytosolic calcium by corticotropin-releasing factor (CRF) in midbrain dopamine neurons.

79 k indicates a crucial role for corticotropin-releasing factor (CRF) in neurobiological responses asso

80 ole of the stress neurohormone corticotropin-releasing factor (CRF) in stress-induced binge eating in

81 work hypothesizing a role for corticotropin-releasing factor (CRF) in the IC during craving and rela

82 tionship between dynorphin and corticotropin-releasing factor (CRF) in the induction of dysphoria, th

83 ith the stress-related peptide corticotropin-releasing factor (CRF) in the LC.

84 ibution of the stress hormone, corticotropin-releasing factor (CRF) in the mouse brain.

85 tly described the existence of corticotropin-releasing factor (CRF) in the mouse cochlea.

86 ed following overexpression of corticotropin-releasing factor (CRF) in the NAc of female and male rat

87 thasone (DEX) inhibition, and corticotrophin-releasing factor (CRF) induced activation.

88 d that the stress neurohormone corticotropin-releasing factor (CRF) inhibits 5-HT neurons in the dors

89 ggests that catecholamines and corticotropin-releasing factor (CRF) interact in a serial manner to ac

90 ces the release of the peptide corticotropin-releasing factor (CRF) into the ventral tegmental area (

91 Corticotropin-releasing factor (CRF) is an important link between stre

92 The stress neuropeptide corticotropin releasing factor (CRF) is anxiogenic and is produced by

93 Corticotropin-releasing factor (CRF) is critical for the endocrine, au

94 emonstrate that, in the vBNST, corticotropin releasing factor (CRF) is expressed in neurons that inne

95 Corticotropin-releasing factor (CRF) is expressed in the Ce, has a rol

96 Corticotrophin-releasing factor (CRF) is expressed in the central nucle

97 Corticotropin releasing factor (CRF) is the primary mediator of stress

98 Corticotropin-releasing factor (CRF) mediates anxiogenic responses by

99 nous neuropeptide Y (NPY) and corticotrophin-releasing factor (CRF) modulate the responses of the bas

100 t experiments examined whether corticotropin-releasing factor (CRF) modulates memory consolidation vi

101 Corticotrophin-releasing factor (CRF) modulates the influence of stress

102 Corticotropin-releasing factor (CRF) mRNA expression in the hypothalam

103 alcohol exposure contains ~80% corticotropin-releasing factor (CRF) neurons and that the optogenetic

104 gh it has long-been known that corticotropin-releasing factor (CRF) neurons are prominent within the

105 on, potentially by activating corticotrophin releasing factor (CRF) neurons in the anterolateral cell

106 d activates a subpopulation of corticotropin-releasing factor (CRF) neurons in the bed nucleus of the

107 pecifically recruited GABA and corticotropin-releasing factor (CRF) neurons in the mPFC and produced

108 hip between corticosterone and corticotropin-releasing factor (CRF) on both beta-amyloid (Abeta) and

109 of an intravenous injection of corticotropin-releasing factor (CRF) on fructose malabsorption and the

110 nce of the stress neuropeptide corticotropin-releasing factor (CRF) on these responses.

111 was to examine the ability of corticotropin releasing factor (CRF) or antibody to insulin growth fac

112 ry but did not increase either corticotropin-releasing factor (CRF) or corticosterone.

113 , arginine-vasopressin (AVP), corticotrophin-releasing factor (CRF) or tyrosine hydroxylase (TH).

114 Injection of corticotropin-releasing factor (CRF) or urocortin III, key mediators o

115 Corticotropin-releasing factor (CRF) orchestrates the stress response,

116 The corticotropin-releasing factor (CRF) peptide hormone family members co

117 The corticotropin-releasing factor (CRF) plays a key role in a variety of

118 Corticotropin releasing factor (CRF) plays a major role in CNS respons

119 derable evidence suggests that corticotropin-releasing factor (CRF) plays an important role in regula

120 stress-associated neuropeptide corticotropin releasing factor (CRF) produces a profound and reliable

121 The corticotropin-releasing factor (CRF) receptor 1 (CRFR1) is a target fo

122 eta elevation are dependent on corticotropin-releasing factor (CRF) receptor 1 signaling and an intac

123 The corticotropin-releasing factor (CRF) receptor CRFR2 is expressed widel

124 awal was mediated by increased corticotropin releasing factor (CRF) receptor-1 expression and signall

125 Corticotropin-releasing factor (CRF) receptors are found in stress-rel

126 Because corticotropin-releasing factor (CRF) receptors are implicated, we comp

127 emonstrated that activation of corticotropin-releasing factor (CRF) receptors in the caudal dorsomedi

128 lation increases the levels of corticotropin-releasing factor (CRF) receptors in the serotonergic dor

129 Corticotropin-releasing factor (CRF) receptors-which bind the hormone

130 Corticotropin releasing factor (CRF) regulates physiological and behav

131 e stress-related neuropeptide, corticotropin-releasing factor (CRF) regulates the dorsal raphe nucleu

132 e through alterations in brain corticotropin-releasing factor (CRF) regulation of neurocircuitry invo

133 Corticotropin releasing factor (CRF) signaling and CRF neurons in the

134 Corticotropin-releasing factor (CRF) signaling at the CRF1 receptor (C

135 Alterations in corticotropin-releasing factor (CRF) signaling pathways have been impl

136 Activation of corticotropin-releasing factor (CRF) signaling pathways mediates both

137 VN) have been shown to inhibit corticotropin releasing factor (CRF) synthesis via GABA(A) receptors.

138 H secretion by activating the corticotrophin-releasing factor (CRF) system and sympathoadrenal pathwa

139 Dysregulation of the corticotropin-releasing factor (CRF) system has been implicated in man

140 The corticotropin releasing factor (CRF) system in the central amygdala (C

141 The corticotropin releasing factor (CRF) system in the central amygdala (C

142 The corticotropin-releasing factor (CRF) system is the primary central med

143 strated that activation of the corticotropin-releasing factor (CRF) system potentiates MC degranulati

144 ncluding the extrahypothalamic corticotropin-releasing factor (CRF) system, following long-term drug

145 The corticotropin-releasing factor (CRF) system, which is involved in stre

146 gdala (Neo-A) lesions on brain corticotropin-releasing factor (CRF) systems and hypothalamic-pituitar

147 Corticotropin-releasing factor (CRF) that is released from the paraven

148 The corticotropin-releasing factor (CRF) type 1 receptor (CRF1R) for the 4

149 Systemic blockade of corticotropin-releasing factor (CRF) type 1 receptors (CRFR1s) reduces

150 gdala (CeA), ethanol acts via corticotrophin-releasing factor (CRF) type 1 receptors to enhance GABA

151 Corticotropin releasing factor (CRF) within the ventral tegmental area

152 ng peptide, PAC1 receptor, and corticotropin-releasing factor (CRF), (CRF1) receptor.

153 We investigated how corticotrophin releasing factor (CRF), a critical stress response media

154 Here we report that corticotropin-releasing factor (CRF), a neuropeptide released in respo

155 e number of neurons expressing corticotropin releasing factor (CRF), a neuropeptide that has a promin

156 imolecular interaction between corticotropin-releasing factor (CRF), a neuropeptide, and its type 1 r

157 ited different sensitivity to corticotrophin-releasing factor (CRF), a stress hormone that has been i

158 this, the CEA highly expresses corticotropin-releasing factor (CRF), an important modulator of stress

159 excitatory amino acids (EAAs), corticotropin-releasing factor (CRF), and endogenous opioids acting at

160 opeptide related to vertebrate corticotropin-releasing factor (CRF), and its receptor, Dh44R1.

161 r modulation by dopamine (DA), corticotropin-releasing factor (CRF), and their combination (DA plus C

162 The neuroactive substances corticotropin-releasing factor (CRF), arginine-vasopressin (AVP), hist

163 is thought to communicate via corticotropin-releasing factor (CRF), but studies have yet to examine

164 The neuropeptide, corticotropin-releasing factor (CRF), coordinates the physiological an

165 Corticotropin-releasing factor (CRF), encoded by the CRH gene, is a ke

166 ed receptor B1 family includes corticotropin-releasing factor (CRF), growth hormone-releasing hormone

167 axis-activating neuropeptide, corticotropin-releasing factor (CRF), may be the keystone in drug-indu

168 es indicate the involvement of corticotropin-releasing factor (CRF), noradrenaline, dopamine, glutama

169 Corticotropin-releasing factor (CRF), originally characterized as the

170 s for the stress neuropeptide, corticotropin-releasing factor (CRF), that render the locus coeruleus

171 Corticotropin-releasing factor (CRF), the major stress peptide in the

172 e focus is on the receptor for corticotropin-releasing factor (CRF), the orchestrator of the stress r

173 Corticotropin-releasing factor (CRF), the stress-related neuropeptide,

174 ticotropes are stimulated with corticotropin releasing factor (CRF), whereupon SSTR2 exits the compar

175 g the stress-sensitive peptide corticotropin-releasing factor (CRF), which has been identified in cri

176 oradrenergic substrates [via a corticotropin-releasing factor (CRF)-dependent mechanism] that regulat

177 nd inhibitory transmission in corticotrophin-releasing factor (CRF)-expressing dorsal-medial (mpd) ne

178 Here, we demonstrate that corticotrophin-releasing factor (CRF)-expressing neurons in the central

179 en shown previously to cause a corticotropin-releasing factor (CRF)-mediated increase in tonic locus

180 Corticotropin-releasing factor (CRF)-mediated mechanisms in the bed nu

181 in the brain that counteracts corticotropin-releasing factor (CRF)-mediated stress and anxiety sympt

182 D is functionally expressed on corticotropin-releasing factor (CRF)-positive BNST cells implicated in

183 tin 1 (Ucn 1) is an endogenous corticotropin releasing factor (CRF)-related peptide.

184 the stress-sensitive peptide, corticotropin releasing factor (CRF).

185 ocorticoid receptors (GRs) and corticotropin-releasing factor (CRF).

186 opaminergic neurons expressing corticotropin-releasing factor (CRF).

187 e prototypical stress hormone, corticotropin releasing factor (CRF).

188 e stress-related neuropeptide, corticotropin-releasing factor (CRF).

189 the anxiogenic neuromodulator, corticotropin releasing factor (CRF).

190 he stress-related neurohormone corticotropin-releasing factor (CRF).

191 l antibody, CTRND05, targeting corticotropin-releasing factor (CRF).

192 that produce the neuropeptide corticotropin-releasing factor (CRF).

193 uding neuropeptide Y (NPY) and corticotropin-releasing factor (CRF).

194 The mammalian corticotropin releasing factor (CRF)/urocortin (Ucn) peptide hormones

195 nal aggression) is impaired by corticotropin-releasing factor-(CRF) related peptides, but where these

196 tested the hypothesis that the corticotropin-releasing factor (CRF1) antagonist GSK561679 differentia

197 tment of brain stress systems (corticotropin-releasing factor, dynorphin, norepinephrine, hypocretin,

198 teral amygdala (BLA) away from corticotropin releasing factor-expressing (CRF(+)) centrolateral amygd

199 transcriptionally activated in corticotropin releasing factor-expressing cells.

200 region-specific alterations of corticotropin-releasing factor expression and promoter methylation, ch

201 neuropeptides vasopressin and corticotropin-releasing factor facilitate, while serotonin inhibits, a

202 rs, which bind peptides of the corticotropin releasing factor family and are key mediators in the str

203 NGF and the hormone urotensin (corticotropin-releasing factor family ligand).

204 RasGRP1, a guanine nucleotide-releasing factor for Ras, plays an important role in pos

205 Human recombinant histamine-releasing factor has also recently been shown to induce

206 al. provide a causal link between histamine-releasing factor (HRF) interactions with IgE and food al

207 lacks a secreted factor related to histamine-releasing factor (HRF).

208 Histamine-releasing factor (HRF; also known as translationally con

209 ther suggest that an activated corticotropin-releasing factor/hypothalamic-pituitary-adrenal axis sys

210 thropin-releasing hormone, and corticotropin-releasing factor immunoreactive cells in the paraventric

211 s the physiological actions of corticotropin-releasing factor in the anterior pituitary gland and the

212 l axis, including signaling by corticotropin-releasing factor, in the pathophysiology of PTSD.

213 A1 and aromatase enhanced local bone marrow-releasing factors, including androgen receptor, estrogen

214 Corticotropin-releasing factor infusions into LA impair the consolidat

215 Corticotropin-releasing factor infusions into the central nucleus of t

216 While corticotrophin releasing factor is the prototypic member of this class,

217 cleave both factor IX peptide bonds prior to releasing factor IX abeta.

218 s in restraint-induced Fos and corticotropin-releasing factor mRNA expression in the neurosecretory r

219 cting to vasopressinergic and corticotrophin releasing factor neurons in the paraventricular nucleus,

220 acts with the neuromodulators, corticotropin-releasing factor, norepinephrine, dopamine, and serotoni

221 role of brain stress systems (corticotropin-releasing factor, norepinephrine, orexin [hypocretin], v

222 l impact of treatment with such hypothalamic releasing factors on recovery from critical illness as w

223 lockade of the stress hormone corticotrophin-releasing factor or of peripheral GC action, as well as

224 ior hypothalamus that may gate corticotropin-releasing factor output from the amygdala to the anterio

225 n of the brain stress system's corticotropin-releasing factor outside of the hypothalamus in the exte

226 d (i.e., serotonin, dynorphin, corticotropin-releasing factor, oxytocin).

227 Cohesin dynamics are controlled by the releasing factors Pds5 and Wapl and the cohesin stabiliz

228 this region of receptors for corticotrophin-releasing factor, pituitary adenylate cyclase-activating

229 appetite regulation, including corticotropin releasing factor, pro-opiomelanocortin B, and glucose tr

230 logical consequence of central corticotropin-releasing factor receptor (CRF-R) activation.

231 ed differential involvement of corticotropin-releasing factor receptor (CRFR) 1 and 2 in acute stress

232 f signaling through the type 1 corticotropin-releasing factor receptor (CRFR1).

233 dministration of the selective corticotropin-releasing factor receptor 1 (CRF(1)) antagonist R121919

234 n, we examined the role of the corticotropin-releasing factor receptor 1 (CRF(1)) in this behavior as

235 haracterize the effects of the corticotropin-releasing factor receptor 1 (CRF-R1) antagonist, GW87600

236 (NE) receptors (alpha1) via a corticotropin-releasing factor receptor 1 (CRF-R1)-dependent mechanism

237 g the efficacy of GSK561679, a corticotropin-releasing factor receptor 1 (CRF1 receptor) antagonist i

238 We describe a novel corticotropin-releasing factor receptor 1 (CRF1) antagonist with advan

239 Blockade of corticotropin-releasing factor receptor 1 (CRF1) suppresses stress-ind

240 member of a class B GPCR, the corticotropin releasing factor receptor 1 (CRF1R).

241 Corticotropin-releasing factor receptor 1 (CRFR1) mediates the physiol

242 what has been observed for the corticotropin-releasing factor receptor 1 (CRFR1), SAP97 expression is

243 r-activated receptor gamma and corticotropin-releasing factor receptor 1 were notable exceptions.

244 ivated by either neurokinin I, corticotropin-releasing factor receptor 1, or dopamine D(1) receptors.

245 Mice deficient in corticotropin-releasing factor receptor 2 (CRF2) (C57BL/6J:129Sv backg

246 ed significant upregulation of corticotropin releasing factor receptor 2 (CrfR2) in the amygdala of m

247 constitutive activation of the corticotropin-releasing factor receptor family homologue SEB-3.

248 d psychological stress through corticotropin-releasing factor receptor subtype 1 (CRF(1)) expressed o

249 dy we investigated the role of corticotropin-releasing factor receptor subtype 2 (CRF(2)) as a modula

250 ent study examines the role of corticotropin releasing factor receptor subtypes 1 and 2 (CRFR1, CRFR2

251 CRF(2(a))R and the homologous corticotropin-releasing factor receptor type 1 (CRF(1)R) possessing a

252 vestigated whether blockade of corticotropin-releasing factor receptor type 1 (CRF-R1) could prevent

253 ctions in anandamide driven by corticotropin-releasing factor receptor type 1 (CRF1) potentiation of

254 re the interaction between the corticotropin releasing factor receptor type 1 (CRF1R) and its native

255 ed interactions of the class B corticotropin-releasing factor receptor type 1 (CRF1R) with two peptid

256 Corticotropin-releasing factor receptor type 1 (CRFR1) is involved in

257 compartments, we show that the corticotropin-releasing factor receptor type 1 has a specific monomer/

258 nsmembrane domain of the human corticotropin-releasing factor receptor type 1 in complex with the sma

259 The corticotropin-releasing factor receptor type 1 is a class B receptor w

260 librium is established for the corticotropin-releasing factor receptor type 1.

261 Corticotropin-releasing factor receptor type 2 (CRFR2) has been implic

262 central stress response, while corticotropin-releasing factor receptor type 2 (CRFR2) has been sugges

263 bserved abnormal expression of corticotropin-releasing factor receptor type 2 (CRFR2) to be associate

264 The corticotropin-releasing factor receptor type 2a (CRF(2(a))R) possesses

265 Corticotropin-releasing factor receptor-1 (CRF(1)) mediates the stress

266 pyrazolo[1,5-a]-1,3,5-triazine corticotropin releasing factor receptor-1 (CRF(1)) receptor antagonist

267 pyrazolo[1,5-a]-1,3,5-triazine corticotropin releasing factor receptor-1 (CRF(1)) receptor antagonist

268 is unaffected by alpha1-AR and corticotropin-releasing factor receptor-1 (CRFR(1)) antagonists, but i

269 tention were attenuated by the corticotropin-releasing factor receptor-1 antagonist antalarmin but no

270 of the analogous domain of the corticotropin-releasing factor receptor.

271 Corticotropin-Releasing Factor Receptors (CRFRs) are class B1 G-protei

272 Corticotropin-releasing factor receptors (CRFRs), class B G protein-co

273 Codon selection, releasing factor recognition sequence and specific intro

274 Urocortin 3 (Ucn 3) is a corticotrophin-releasing factor related neuropeptide highly expressed i

275 it has been shown to increase corticotropin-releasing factor release in extrahypothalamic brain regi

276 ion-like protein (RepA-WH1) into the E. coli releasing factor RF1 promotes its aggregation and enable

277 Alterations in central corticotropin-releasing factor signaling pathways have been implicated

278 n-gamma (IFN-gamma) and induce cytolysis via releasing factors such as perforin, which permeabilizes

279 s), (4) the (gastrointestinal) corticotropin-releasing factor system, and (5) the intestinal response

280 In addition, corticotropin-releasing factor systems were shown to facilitate memory

281 s probed using a dexamethasone/corticotropin-releasing factor test.

282 spected of initiating childhood leukaemia by releasing factors that cause DNA damage in cord blood an

283 strocytes play a key role in this process by releasing factors that promote the formation of excitato

284 role in maintaining vascular homeostasis by releasing factors that regulate local blood flow, system

285 counteracting the functions of corticotropin-releasing factor, the primary stress-mediating neuropept

286 lin, nesfatin-1, somatostatin, corticotropin-releasing factor, thyrotropin-releasing hormone and calc

287 buting ions, removing neurotransmitters, and releasing factors to influence blood flow and neuronal a

288 ation between histamine release to histamine releasing factor/translationally controlled tumor protei

289 hesis was investigated for the corticotropin-releasing factor type 1 (CRF(1)) receptor using a novel

290 Corticotropin releasing factor type 1 (CRF1) is a key component in the

291 Activation of corticotropin-releasing factor type 1 (CRF1) receptors in the CeA play

292 ve effect is mediated via the corticotrophin-releasing factor type 1 receptor (CRF1R, also known as C

293 peated social stress decreased corticotropin-releasing factor type 1 receptor and increased mu-opioid

294 We found that corticotropin-releasing factor type 1 receptor within the paraventricu

295 LTCC-based mechanism; instead, corticotropin-releasing factor type 1 receptors (CRF1s) mediate alcoho

296 LTCC-based mechanism; instead, corticotropin-releasing factor type 1 receptors (CRF1s) mediate alcoho

297 The corticotropin-releasing factor type 2 receptor (CRFR2) is suggested to

298 hat the mechanism involved the corticotropin-releasing factor type 2 receptor, cAMP elevation, and ac

299 , which required activation of corticotropin-releasing factor type-1 (CRF-R1) receptors.

300 ombined administration of those hypothalamic releasing factors, which have been identified as suppres